39 completed, 3 active not recruiting, 3 terminated, 2 recruiting. 29 Phase 1, 7 Phase 3, 6 Phase 2, 2 Not applicable, 1 Phase 4.
Follow isavuconazole: new trials by email Literature Review of isavuconazole trials Research Report on isavuconazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome Monzosertib, Posaconazole, Isavuconazole - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 42 | 2027-01-01 | 2026-08-21 |
| Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study Amphotericin B, Isavuconazole - Mucormycosis | Active not recruiting | Qiu Ye | 150 | 2025-05-15 | 2025-09-25 | |
| Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole - Mucormycosis in Hematologic Malignancies | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2025-03-25 | 2025-09-22 | |
| Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis transbronchoscopic interventional debridement - Pulmonary Mucormycosis | Not applicable | Unknown | Beijing Tsinghua Chang Gung Hospital | 30 | 2024-07-30 | 2024-07-11 |
| Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children Theraputic drug monitoring, Isavuconazole - Aspergillosis Invasive, Mucormycosis | Not applicable | Recruiting | Shanghai Children's Medical Center | 200 | 2024-06-06 | 2024-12-13 |
| Isavuconazole Therapeutic Drug Monitoring in Transplant Recipients Isavuconazole - Invasive Fungal Infections, Lung Transplantation | Completed | Zhibin Xu | 110 | 2024-01-01 | 2026-07-21 | |
| Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi Isavuconazole - Invasive Fungal Disease | Phase 4 | Completed | Pfizer | 70 | 2023-02-07 | 2026-05-27 |
| Azole-echinocandin Combination Therapy for Invasive Aspergillosis Azole, Anidulafungin - Invasive Aspergillosis | Phase 3 | Terminated | Erasmus Medical Center | 66 | 2021-05-11 | 2024-05-07 |
| Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis Isavuconazonium Injection [Cresemba], Placebo - Severe Acute Respiratory Syndrome Coronavirus 2, Aspergillosis Invasive | Phase 3 | Terminated | Jeffrey Jenks, MD, MPH | 8 | 2021-03-16 | 2022-11-25 |
| A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions. Isavuconazole - Invasive Aspergillosis, Mucormycosis | Completed | Pfizer | 307 | 2021-03-10 | 2025-12-09 | |
| A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants Acalabrutinib, Fluconazole, Isavuconazole - Healthy Volunteers | Phase 1 | Completed | Acerta Pharma BV | 30 | 2020-01-03 | 2021-12-01 |
| A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Isavuconazonium sulfate IV, Isavuconazonium sulfate capsules - Healthy Subjects | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 17 | 2019-09-24 | 2024-11-20 |
| A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants Isavuconazonium sulfate - Invasive Mucormycosis, Invasive Aspergillosis | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 31 | 2019-08-22 | 2024-12-05 |
| Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) TEDD-R, TEDDI-R, Ibrutinib - Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2019-06-27 | 2026-10-16 |
| Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis AK1820, Voriconazole - Deep Mycosis | Phase 3 | Completed | Asahi Kasei Therapeutics Corporation | 103 | 2018-04-16 | 2021-05-14 |
| VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B - Invasive Aspergillosis, Invasive Pulmonary Aspergillosis | Phase 2 | Terminated | Vical | 4 | 2018-02-20 | 2019-02-27 |
| A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients isavuconazonium sulfate - intravenous, isavuconazonium sulfate - oral - Hematological Malignancy | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 49 | 2017-10-02 | 2024-11-19 |
| Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) Isavuconazole - Hematologic Malignancy, Myeloproliferative Disorder | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 99 | 2017-05-04 | 2025-05-16 |
| Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia Isavuconazole - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Completed | M.D. Anderson Cancer Center | 65 | 2017-03-28 | 2021-10-26 |
| Registry of Patients Treated With Systemic Mold-Active Triazoles Isavuconazonium sulfate, Voriconazole, Posaconazole - Invasive Fungal Infection | Completed | Astellas Pharma Global Development, Inc. | 2015 | 2017-03-16 | 2024-10-21 |
Showing 20 of 49. Sign in to see all of them.
Invasive Fungal Infections (6) · Mucormycosis (5) · Aspergillosis (3) · Hematologic Neoplasms (3) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (2) · Candidemia (1) · Candidiasis, Invasive (1) · Cryptococcosis (1) · Invasive Pulmonary Aspergillosis (1) · Mycoses (1) · Myeloproliferative Disorders (1) · Neutropenia (1)
Astellas Pharma Global Development, Inc. (24) · Astellas Pharma Inc (7) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Pfizer (2) · Acerta Pharma BV (1) · Asahi Kasei Therapeutics Corporation (1) · Basilea Pharmaceutica (1) · Beijing Tsinghua Chang Gung Hospital (1) · Erasmus Medical Center (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jeffrey Jenks, MD, MPH (1) · Memorial Sloan Kettering Cancer Center (1) · Qiu Ye (1) · Shanghai Children's Medical Center (1)
United States (38) · China (9) · Belgium (6) · Germany (6) · France (5) · Canada (4) · Spain (4) · Argentina (3) · Australia (3) · Brazil (3) · Chile (3) · India (3) · Israel (3) · Italy (3) · Mexico (3)
Rahul Lakhotia, M.D. (2) · Abhishek Maiti, MBBS (1) · Bart Rijnders, MD, PhD (1) · George Thompson, MD (1) · Jeffrey Jenks, MD, MPH (1) · Juan Wu, PhD (1) · Mammen P Mammen, MD, FIDSA (1) · Manting Liu, MD (1) · Martin Hoenigl, MD (1) · Oliver Cornely, MD (1)
PMID 37185921, PMID 25624327, PMID 25902926, PMID 26684607, PMID 26969258, PMID 27169478, PMID 27185799, PMID 28472247, PMID 30289478, PMID 30962330, PMID 32236406, PMID 34031051, PMID 35191210, PMID 36307059, PMID 37641932, PMID 38419156, PMID 39378343, PMID 39443403, PMID 39540734, PMID 40830172
2005 (1), 2017 (1), 2018 (1)